Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  carmustine
Find trials that include:  Any drugs shown
Results 1-21 of 21 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Lymphoma
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: 12338, NCI-2015-00185, 093270, 2012-0005534-11, NCT00491491, NCT02366663
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 1409.00, NCI-2010-00130, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2000.00, NCI-2013-00701, 8357, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
Yttrium Y 90 Daclizumab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Recurrent or Refractory Hodgkin’s Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0003, NCI-2013-01512, 120003, P11859, NCT01468311
Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 201101864, NCI-2011-00728, 09-0042, NCT00882895
Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2292.00, NCI-2009-01302, 2292, FH 2292/X05287, X05287, NCT00992446
Combination Chemotherapy with or without Autologous Stem Cell Transplant in Treating Patients with Central Nervous System B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 70
Trial IDs: CALGB 51101, NCI-2012-00110, CDR0000721927, NCT01511562
Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: 13-020, NCI-2013-01365, NCT01908777
Combination Chemotherapy before Peripheral Blood Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 201312115, NCI-2013-02212, NCT01969435
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Primary Refractory or Relapsed Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 08179, NCI-2011-03334, 112221, 116766, 119517, NCT01476839
Yttrium Y 90 Basiliximab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Mature T-cell Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 14349, NCI-2015-00019, 116688, NCT02342782
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients with Lymphoma with HIV Infection
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 66
Trial IDs: 2673.00, NCI-2014-02395, 2673, NCT02343666
Start Over